1. Home
  2. EQBK vs KALV Comparison

EQBK vs KALV Comparison

Compare EQBK & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Equity Bancshares Inc.

EQBK

Equity Bancshares Inc.

HOLD

Current Price

$45.77

Market Cap

976.3M

Sector

Finance

ML Signal

HOLD

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$20.86

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EQBK
KALV
Founded
2002
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
976.3M
1.0B
IPO Year
2015
2014

Fundamental Metrics

Financial Performance
Metric
EQBK
KALV
Price
$45.77
$20.86
Analyst Decision
Hold
Strong Buy
Analyst Count
3
5
Target Price
$51.33
$32.60
AVG Volume (30 Days)
98.6K
1.2M
Earning Date
04-14-2026
05-09-2026
Dividend Yield
1.58%
N/A
EPS Growth
N/A
N/A
EPS
1.23
N/A
Revenue
N/A
$50,000,000.00
Revenue This Year
$74.58
$187.19
Revenue Next Year
$5.11
$54.93
P/E Ratio
$37.00
N/A
Revenue Growth
N/A
495.66
52 Week Low
$36.04
$9.83
52 Week High
$50.07
$21.31

Technical Indicators

Market Signals
Indicator
EQBK
KALV
Relative Strength Index (RSI) 52.64 61.63
Support Level $44.38 $14.66
Resistance Level $48.05 $21.31
Average True Range (ATR) 0.99 1.22
MACD 0.07 0.01
Stochastic Oscillator 48.18 83.59

Price Performance

Historical Comparison
EQBK
KALV

About EQBK Equity Bancshares Inc.

Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 77 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Share on Social Networks: